ondasdechoque.org
PT-BR

Plantar heel pain / plantar fasciopathy · Randomized trial · 2022

Does treating points in the leg and pelvis help heel pain more than treating the heel?

In this trial, both ways of giving focused shockwave were followed by better foot scores. People treated on points along the leg and pelvis improved more: by four months their foot problem score (0–100) had dropped about twice as much as with treatment at the heel.

Possible early help from treating leg and pelvis points
adults with long-lasting heel pain
30
sessions, one a week, in both groups
3
after the last session
4 mo

Good to know: Only the leg and pelvis group also received manual release.

Tognolo L, Giordani F, Biz C, et al. European Journal of Physical and Rehabilitation Medicine, 2022 · Read the paper ↗

How this study worked

Shockwave on leg andpelvis points11 peopleShockwave at the heel19 people
People were assigned to the groups by lot. Each dot is one person.

What happened

Foot problems: leg and pelvis points vs heel

Difference in change, 0–100 foot score, with likely range · below 0 favours leg and pelvis points

After one session the difference was about 4 points and uncertain. From the third visit on, foot scores improved about 19 to 21 points more with treatment on leg and pelvis points, with wide ranges.
Show the numbers
Difference (points on the 0–100 foot problem score)likely range
After 1 session−3.9−20 to 12.1
After 2 sessions−18.9−35 to −2.9
1 month after−20.7−37.3 to −4.1
4 months after−19.9−36.7 to −3.2

The treatment

Shockwave on leg and pelvis points

Focused, once a week for 3 weeks

Focused wavesMeet at a focal zone below the skin
Sessions
3, one a week
Pulses
1,500 per point · 3 or 4 points on the leg and pelvis
Strength
0.05–0.167mJ/mm² · 5 per second
Numbing
Not mentioned
Device
Duolith SD1 T-Top (Storz Medical)
Everyone also got
Manual release of a point if it had not loosened

Shockwave at the heel

Focused, once a week for 3 weeks

Focused wavesMeet at a focal zone below the skin
Sessions
3, one a week
Pulses
2,000 per point · the most tender spot on the heel
Strength
0.20–0.32mJ/mm² · 5 per second
Numbing
Not mentioned
Device
Duolith SD1 T-Top (Storz Medical)

Compared with: The same focused shockwave given at the most tender spot on the heel

Settings are what each study used, not a prescription.

Who took part

30 adults in Padua, Italy, with heel pain for at least 3 months despite other care; the leg-point group had fewer women (45% vs 84%).

hollow squares: no final score

Shockwave on leg and pelvis points11 people
Shockwave at the heel15 of 19 measured
26 of 30 people (87%) had a final score.

Side effects

The study does not report side effects.

All the numbers and the full appraisal
FROM THE FULL PAPER

The results, in numbers.

Adults at one Padua outpatient clinic (April 2019–February 2020) with plantar fasciitis for ≥3 months despite drugs, exercise or insoles, and pain ≥5 on VAS. Mean age 54.7 versus 59.3 years; women 45.5% versus 84.2%. Previous foot fracture or surgery, steroid injection within 3 months, diabetes, vascular disease and suspected fibromyalgia were excluded.

ESWT on myofascial points11randomized

People; all 11 received the allocated treatment and were analysed. If a patient had bilateral symptoms, the most symptomatic foot was scored.

ESWT at the heel19randomized

People; 4 dropped out (1 after the second and 3 after the third session; Figure 1: 1 lost to follow-up, 3 discontinued, reasons not given) and were excluded from analysis. Table I is headed N=15 but its sex counts add to 19.

Foot function (17-iFFI)4 reported outcomes
01
Before the second weekly session (T2)

Foot function (17-iFFI)

17-Italian Foot Function Index (17-iFFI) Score points, change from baseline (T1)

means
GroupnBaselineReported change
ESWT on myofascial points11—-10.5 (SD 12.6)
ESWT at the heel15—-6.6 (SD 11.6)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Adjusted least-squares mean difference in change-3.9CI 95% -20 to 12.1p = 1.0000

Myofascial-point ESWT minus heel ESWT

Mixed model on change from baseline (group, time, group×time, first-order autoregressive covariance); least-squares means with Bonferroni-adjusted 95% CI and P

-23.9Equal results 016

17-iFFI fell in both groups. The model favoured the myofascial-point group overall (group effect P=0.0016; interaction P=0.0926), with adjusted differences significant at T3, T4 and T5 but not at T2. These are differences in change between two active shockwave approaches among the 26 people analysed.

Analysis details and source

Group columns are observed mean (SD) change from baseline; the effect is the model estimate. Completers only: 11 versus 15 of 30 randomized. 17-iFFI: 0 best, 100 worst; range 0–100 per Methods p. 88. Gender-adjusted analysis reported as similar, data not shown.

02
Before the third weekly session (T3)

Foot function (17-iFFI)

17-Italian Foot Function Index (17-iFFI) Score points, change from baseline (T1)

means
GroupnBaselineReported change
ESWT on myofascial points11—-21.8 (SD 23)
ESWT at the heel15—-2.9 (SD 8.5)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Adjusted least-squares mean difference in change-18.9CI 95% -35 to -2.9p = 0.0138

Myofascial-point ESWT minus heel ESWT

Mixed model on change from baseline (group, time, group×time, first-order autoregressive covariance); least-squares means with Bonferroni-adjusted 95% CI and P

-39.2Equal results 04.2

17-iFFI fell in both groups. The model favoured the myofascial-point group overall (group effect P=0.0016; interaction P=0.0926), with adjusted differences significant at T3, T4 and T5 but not at T2. These are differences in change between two active shockwave approaches among the 26 people analysed.

Analysis details and source

Group columns are observed mean (SD) change from baseline; the effect is the model estimate. Completers only: 11 versus 15 of 30 randomized. 17-iFFI: 0 best, 100 worst; range 0–100 per Methods p. 88. Gender-adjusted analysis reported as similar, data not shown.

03
One month after the last session (T4)

Foot function (17-iFFI)

17-Italian Foot Function Index (17-iFFI) Score points, change from baseline (T1)

means
GroupnBaselineReported change
ESWT on myofascial points11—-36.1 (SD 24.2)
ESWT at the heel15—-15.41 (SD 12.1)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Adjusted least-squares mean difference in change-20.7CI 95% -37.3 to -4.1p = 0.0084

Myofascial-point ESWT minus heel ESWT

Mixed model on change from baseline (group, time, group×time, first-order autoregressive covariance); least-squares means with Bonferroni-adjusted 95% CI and P

-41.8Equal results 04.5

17-iFFI fell in both groups. The model favoured the myofascial-point group overall (group effect P=0.0016; interaction P=0.0926), with adjusted differences significant at T3, T4 and T5 but not at T2. These are differences in change between two active shockwave approaches among the 26 people analysed.

Analysis details and source

Group columns are observed mean (SD) change from baseline; the effect is the model estimate. Completers only: 11 versus 15 of 30 randomized. 17-iFFI: 0 best, 100 worst; range 0–100 per Methods p. 88. Gender-adjusted analysis reported as similar, data not shown.

04
Four months after the last session (T5)

Foot function (17-iFFI)

17-Italian Foot Function Index (17-iFFI) Score points, change from baseline (T1)

means
GroupnBaselineReported change
ESWT on myofascial points11—-40.5 (SD 26.8)
ESWT at the heel15—-20.5 (SD 14.6)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Adjusted least-squares mean difference in change-19.9CI 95% -36.7 to -3.2p = 0.0128

Myofascial-point ESWT minus heel ESWT

Mixed model on change from baseline (group, time, group×time, first-order autoregressive covariance); least-squares means with Bonferroni-adjusted 95% CI and P

-41.1Equal results 04.4

17-iFFI fell in both groups. The model favoured the myofascial-point group overall (group effect P=0.0016; interaction P=0.0926), with adjusted differences significant at T3, T4 and T5 but not at T2. These are differences in change between two active shockwave approaches among the 26 people analysed.

Analysis details and source

Group columns are observed mean (SD) change from baseline; the effect is the model estimate. Completers only: 11 versus 15 of 30 randomized. 17-iFFI: 0 best, 100 worst; range 0–100 per Methods p. 88. Gender-adjusted analysis reported as similar, data not shown.

Foot and ankle outcome (FAOS)4 reported outcomes
05
Before the second weekly session (T2)

Foot and ankle outcome (FAOS)

Foot and Ankle Outcome Score (FAOS) Score points, change from baseline (T1)

means
GroupnBaselineReported change
ESWT on myofascial points11—6.5 (SD 16.7)
ESWT at the heel15—3.9 (SD 4.9)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Adjusted least-squares mean difference in change2.7CI 95% -9.2 to 14.5p = 1.0000

Myofascial-point ESWT minus heel ESWT

Mixed model on change from baseline (group, time, group×time, first-order autoregressive covariance); least-squares means with Bonferroni-adjusted 95% CI and P

-12Equal results 017.3

FAOS rose in both groups. The model favoured the myofascial-point group (group effect P=0.0072; interaction P=0.0143), with adjusted differences significant at T3, T4 and T5 but not at T2. The four control dropouts are not in these estimates.

Analysis details and source

Group columns are observed mean (SD) change from baseline; the effect is the model estimate. Completers only: 11 versus 15 of 30 randomized. FAOS: 0 worst, 100 best; range 0–100 per Methods p. 88. Gender-adjusted analysis reported as similar, data not shown.

06
Before the third weekly session (T3)

Foot and ankle outcome (FAOS)

Foot and Ankle Outcome Score (FAOS) Score points, change from baseline (T1)

means
GroupnBaselineReported change
ESWT on myofascial points11—15.4 (SD 14.8)
ESWT at the heel15—0.7 (SD 8.8)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Adjusted least-squares mean difference in change14.6CI 95% 2.8 to 26.5p = 0.0091

Myofascial-point ESWT minus heel ESWT

Mixed model on change from baseline (group, time, group×time, first-order autoregressive covariance); least-squares means with Bonferroni-adjusted 95% CI and P

-3.2Equal results 029.7

FAOS rose in both groups. The model favoured the myofascial-point group (group effect P=0.0072; interaction P=0.0143), with adjusted differences significant at T3, T4 and T5 but not at T2. The four control dropouts are not in these estimates.

Analysis details and source

Group columns are observed mean (SD) change from baseline; the effect is the model estimate. Completers only: 11 versus 15 of 30 randomized. FAOS: 0 worst, 100 best; range 0–100 per Methods p. 88. Gender-adjusted analysis reported as similar, data not shown.

07
One month after the last session (T4)

Foot and ankle outcome (FAOS)

Foot and Ankle Outcome Score (FAOS) Score points, change from baseline (T1)

means
GroupnBaselineReported change
ESWT on myofascial points11—23.1 (SD 14.1)
ESWT at the heel15—10.5 (SD 10)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Adjusted least-squares mean difference in change12.8CI 95% 0.7 to 25p = 0.0341

Myofascial-point ESWT minus heel ESWT

Mixed model on change from baseline (group, time, group×time, first-order autoregressive covariance); least-squares means with Bonferroni-adjusted 95% CI and P

-3Equal results 028

FAOS rose in both groups. The model favoured the myofascial-point group (group effect P=0.0072; interaction P=0.0143), with adjusted differences significant at T3, T4 and T5 but not at T2. The four control dropouts are not in these estimates.

Analysis details and source

Group columns are observed mean (SD) change from baseline; the effect is the model estimate. Completers only: 11 versus 15 of 30 randomized. FAOS: 0 worst, 100 best; range 0–100 per Methods p. 88. Gender-adjusted analysis reported as similar, data not shown.

08
Four months after the last session (T5)

Foot and ankle outcome (FAOS)

Foot and Ankle Outcome Score (FAOS) Score points, change from baseline (T1)

means
GroupnBaselineReported change
ESWT on myofascial points11—26.9 (SD 18.5)
ESWT at the heel15—12.9 (SD 11.4)

SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.

Adjusted least-squares mean difference in change14.2CI 95% 1.9 to 26.5p = 0.0163

Myofascial-point ESWT minus heel ESWT

Mixed model on change from baseline (group, time, group×time, first-order autoregressive covariance); least-squares means with Bonferroni-adjusted 95% CI and P

-3.2Equal results 029.7

FAOS rose in both groups. The model favoured the myofascial-point group (group effect P=0.0072; interaction P=0.0143), with adjusted differences significant at T3, T4 and T5 but not at T2. The four control dropouts are not in these estimates.

Analysis details and source

Group columns are observed mean (SD) change from baseline; the effect is the model estimate. Completers only: 11 versus 15 of 30 randomized. FAOS: 0 worst, 100 best; range 0–100 per Methods p. 88. Gender-adjusted analysis reported as similar, data not shown.

How treatment was delivered
Device and modality

Focused shockwaves from a Duolith SD1 T-Top device (Storz Medical), three sessions one week apart in both arms. Anaesthesia was not reported.

Experimental arm

Before each session, 3 or 4 myofascial points of the lower limbs and pelvis were chosen by Fascial Manipulation (Stecco) palpation; 1,500 shocks per point at 5 Hz and 0.05–0.167 mJ/mm², set by pain threshold. If a point had not loosened, treatment was completed manually until release.

Control arm

2,000 shocks at 0.20–0.32 mJ/mm² (by pain threshold) and 5 Hz over one spot, the point of maximal tenderness on the medial calcaneal tubercle. This is an active comparator, not a sham.

Co-interventions

Manual completion of myofascial release was allowed only in the experimental arm. Other co-treatments, medication rules and exercise advice were not reported.

HARMS & TOLERABILITY

Adverse events were not reported for either group. The authors say only that adverse effects are extremely rare at the energy chosen; this is a statement, not a count, so harms are unknown rather than zero. Reasons for the four control dropouts were not given. Conflicts of interest: none declared. Funding: not stated.

LIMITS OF THE ANALYSIS

Author-reported: unequal numbers analysed per group, follow-up too short to study recurrence, and different shock counts between arms (1,500 per point at 3–4 points versus 2,000 at one spot).

Extractor interpretation: open-label design with self-reported questionnaires; simple Excel RAND allocation without described concealment produced 11 versus 19; only the 26 completers were analysed and all four dropouts were in the heel group, which can bias the comparison.

Extractor interpretation: the experimental arm could also receive manual myofascial release, energy ranges differed, and women were 45.5% versus 84.2% of the groups, so the contrast is not the treatment site alone.

Reporting: ClinicalTrials.gov NCT05090059 was first submitted on 6 September 2021, after enrolment ended in February 2020 (registry record checked). No primary outcome is named in the paper; the registry lists both scales. Table I is headed control N=15 while its sex counts total 19, and Table III labels the comparison "EG vs. TG".

Findings checked against the full source by a separate automated reviewer.

Limitations noted by the reviewers

  • Author-reported: unequal numbers analysed per group, follow-up too short to study recurrence, and different shock counts between arms (1,500 per point at 3–4 points versus 2,000 at one spot).
  • Extractor interpretation: open-label design with self-reported questionnaires; simple Excel RAND allocation without described concealment produced 11 versus 19; only the 26 completers were analysed and all four dropouts were in the heel group, which can bias the comparison.
  • Extractor interpretation: the experimental arm could also receive manual myofascial release, energy ranges differed, and women were 45.5% versus 84.2% of the groups, so the contrast is not the treatment site alone.
  • Reporting: ClinicalTrials.gov NCT05090059 was first submitted on 6 September 2021, after enrolment ended in February 2020 (registry record checked). No primary outcome is named in the paper; the registry lists both scales. Table I is headed control N=15 while its sex counts total 19, and Table III labels the comparison "EG vs. TG".
Research review

Source-linked critical reading

Open-label randomized trial of two focused-shockwave targets

Reading depthMaterial consulted
Technical source record

Full local PDF read: all 9 pages including Tables I–III from page images, Figures 1–4 and captions, Methods, Results, Discussion, Limitations, conflicts of interest and references; trial registry dates checked.

Review statusAI-assisted draft · independent automated checkThis automated check comes before the editor’s clinical review.
Study design

Open-label randomized trial at one Italian outpatient clinic. Excel RAND allocation produced groups of 11 and 19; all received treatment, 4 control patients dropped out and 26 were analysed (11 versus 15). Registration (NCT05090059) was submitted in September 2021, after enrolment had ended.

Participants and setting

Adults at one Padua outpatient clinic (April 2019–February 2020) with plantar fasciitis for ≥3 months despite drugs, exercise or insoles, and pain ≥5 on VAS. Mean age 54.7 versus 59.3 years; women 45.5% versus 84.2%. Previous foot fracture or surgery, steroid injection within 3 months, diabetes, vascular disease and suspected fibromyalgia were excluded.

Treatment protocol

Three weekly sessions with a Duolith SD1 T-Top focused device. Before each session 3–4 myofascial points of the lower limbs and pelvis were chosen by Fascial Manipulation palpation and each received 1,500 shocks at 5 Hz and 0.05–0.167 mJ/mm². Points not released by the shocks were finished by hand.

Comparison

The control group received focused shockwaves at the most tender spot on the medial calcaneal tubercle: 2,000 shocks at 0.20–0.32 mJ/mm² and 5 Hz, weekly for three sessions. Both groups had active treatment; there was no sham or untreated group.

What was measured

Two self-reported questionnaires, the 17-item Italian Foot Function Index (0 best, 100 worst) and the FAOS (0 worst, 100 best), were filled in at baseline, before the second and third sessions, and one and four months after the last session. Analyses used change from baseline in a mixed model. The paper names no single primary outcome.

Results and interpretation

Both groups improved. At one week neither scale differed. From the assessment before the third session (T3) onward the myofascial-point group had larger gains: 17-iFFI adjusted differences −18.9 (95% CI −35.0 to −2.9) at T3, −20.7 (−37.3 to −4.1) at one month and −19.9 (−36.7 to −3.2) at four months; FAOS differences 14.6 (2.8 to 26.5), 12.8 (0.7 to 25.0) and 14.2 (1.9 to 26.5). Wide intervals reflect the small groups, and the four control dropouts are excluded.

Harms and disclosures

Adverse events were not reported for either group. The authors say only that adverse effects are extremely rare at the energy chosen; this is a statement, not a count, so harms are unknown rather than zero. Reasons for the four control dropouts were not given. Conflicts of interest: none declared. Funding: not stated.

Limitations

Open-label self-report, unequal allocation (11 versus 19) without described concealment, and a completers-only analysis with every dropout in the heel group. The experimental arm could also get manual release, energy and shock counts differed, and sex distribution was unbalanced. Registration came after enrolment, no primary outcome is named, Table I lists control N=15 while its sex counts total 19, and follow-up ends at four months.

Applicability

Applies to adults with chronic plantar fasciitis treated by clinicians trained in Fascial Manipulation, comparing two focused-shockwave strategies. It does not compare shockwaves with sham, exercise or usual care, and it does not show which part of the experimental package (site, energy or manual release) mattered.

What stronger evidence needs

A larger prospectively registered trial with concealed allocation, blinded assessors, matched energy and no added manual therapy, analysing everyone randomized, recording adverse events and following people for a year or more.

THE ORIGINAL SOURCE

Read the original article.

Myofascial points treatment with focused extracorporeal shock wave therapy (f-ESWT) for plantar fasciitis: an open label randomized clinical trial.

Tognolo L, Giordani F, Biz C, Bernini A, Ruggieri P, Stecco C, Frigo AC, Masiero S. · European journal of physical and rehabilitation medicine · 2022

Open the publication record or available full-text files.

Checked against the full paper · Clinical review: Dr. Marcus Yu Bin Pai, · How we review →